News

Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.

Neutralizing antibodies were initially lowest among Janssen vaccine recipients, but this all changed 6 months after vaccination.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

Sleep as a shield: A new study reveals that sleeping well before COVID-19 infection reduces the risk of post–COVID-19 condition (long COVID).

Analysis of symptoms present six months or more after SARS-CoV-2 infection was used to develop a composite scoring framework for identifying postacute sequelae of SARS-CoV-2 infection (PASC) as a new condition.

The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.

A clinician talks about reducing antibiotic treatment duration for urinary tract infections (UTI).

Investigators revisit an 80-year-old antimicrobial to reduce its toxicity while preserving its activity against drug resistant gram-negative bacteria.

The Mexican Ministry of Health sent the CDC a list of over 200 US patients who may have been exposed to the fungal infection.

There has been a low uptake of bivalent mRNA booster vaccines in older adults, despite a high efficacy of preventing severe and fatal COVID-19.

The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.

This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.

Screening and treating immigrants for hepatitis C virus infection may be instrumental to eliminating the disease in Canada.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

Five-year cumulative data from 2 phase 3 studies looked at 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy).

Accelerating bivalent booster vaccine campaigns for children could reduce pediatric hospitalizations and school absenteeism.

Anticoagulant treatment for 3 to 6 months was sufficient for the majority of COVID-19 patients with venous thromboembolism, the study authors found.

Education is vital to this group and can help in working towards reducing viral hepatitis.

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

Pfizer's RSVpreF vaccine candidate has shown promising efficacy in preventing severe lower respiratory illness caused by RSV in infants. With the potential approval of RSVpreF, pediatric care could undergo a significant positive change.

The National Institute for Health and Care Excellence (NICE) believes National Health Service (NHS) can use bulevirtide as a treatment option.

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

Stay informed with this concise summary of the week's most significant stories.

A vaccine developer discusses the benefits of this approach and the development behind them.

RSVpreF receives strong support from the FDA's VRBPAC, with positive votes for efficacy and safety. The vaccine shows promise in preventing severe respiratory illness in infants, and an FDA authorization decision is expected in August 2023.

Expanding peripartum prophylaxis could be more cost-effective, but would likely lead to significant over-treatment.